title: Approval of antiobesity drug is "major regression for patients' safety," says health watchdog.
authors.affiliation: London.
authors.forename: Nigel
authors.initials: N
authors.lastname: Hawkes
mesh_terms: D019440:Anti-Obesity Agents / Q000009:adverse effects*; D016642:Bupropion / Q000009:adverse effects*; D017277:Drug Approval; D004338:Drug Combinations; D005060:Europe; D005602:France; D006801:Humans; D009271:Naltrexone / Q000009:adverse effects*; D061214:Patient Safety; D014481:United States
chemical_list: D019440:Anti-Obesity Agents; D004338:Drug Combinations; C000591595:bupropion hydrochloride, naltrexone hydrochoride drug combination; D016642:Bupropion; D009271:Naltrexone